# US 2025/0154486 A1 · Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154486 A1
- Document ID: US20250154486A1
- Status: Published application
- Kind: A1
- Application number: 19/029,948
- Filed: 2025-01-17
- Published: 2025-05-15
- Earliest claimed: 2016-10-14
- Assignees: Precision BioSciences, Inc.
- Applicants: Precision Biosciences, Inc.
- Inventors: Derek Jantz; James Jefferson Smith
- Web page: https://patentgrep.com/patent/US20250154486A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 38/43: Enzymes; Proenzymes; Derivatives thereof
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14141: Use of virus, viral particle or viral elements as a vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.

## Claims

### Claim 1

An engineered meganuclease that recognizes and cleaves a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus, wherein the engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable (HVR1) region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable (HVR2) region.

### Claim 2 (depends on 1)

The engineered meganuclease of claim 1, wherein said recognition sequence is within an ORF of genotype A (SEQ ID NO: 3) and one or more of genotype B (SEQ ID NO: 4), genotype C (SEQ ID NO: 5), genotype D (SEQ ID NO: 6), genotype E (SEQ ID NO: 7), genotype F (SEQ ID NO: 8), and genotype G (SEQ ID NO: 9).

### Claim 3 (depends on 1, 2)

The engineered meganuclease of claim 1 or claim 2, wherein said recognition sequence is within at least one ORF encoding a protein selected from the group consisting of the polymerase (P) protein, the large surface (preS1/preS2/S) protein, the middle surface (preS2/S) protein, and the small surface(S) protein.

### Claim 4 (depends on 1, 2, 3)

The engineered meganuclease of any one of claims 1-3, wherein said recognition sequence comprises SEQ ID NO: 12.

### Claim 5 (depends on 4)

The engineered meganuclease of claim 4, wherein said HVR1 region comprises an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 215-270 of any one of SEQ ID NOs: 22-24 or residues 24-79 of any one of SEQ ID NOs: 25-28.

### Claim 6 (depends on 4, 5)

The engineered meganuclease of claim 4 or claim 5, wherein said HVR1 region comprises residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 22-24, or residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs:
25-28.

### Claim 7 (depends on 4, 5, 6)

The engineered meganuclease of any one of claims 4-6, wherein said HVR1 region comprises residues 215-270 of any one of SEQ ID NOs: 22-24 or residues 24-79 of any one of SEQ ID NOs: 25-28.

### Claim 8 (depends on 4, 5, 6, 7)

The engineered meganuclease of any one of claims 4-7, wherein said HVR2 region comprises an amino acid sequence having at least 80% sequence identity to an amino acid sequence corresponding to residues 24-79 of any one of SEQ ID NOs: 22-24 or residues 215-270 of any one of SEQ ID NOs: 25-28.

### Claim 9 (depends on 4, 5, 6, 7, 8)

The engineered meganuclease of any one of claims 4-8, wherein said HVR2 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 22-24, or residues corresponding to residues 215, 217,219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 25-28.

### Claim 10 (depends on 4, 5, 6, 7, 8, 9)

The engineered meganuclease of any one of claims 4-9, wherein said HVR2 region comprises residues 24-79 of any one of SEQ ID NOs: 22-24 or residues 215-270 of any one of SEQ ID NOs: 25-28.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The engineered meganuclease of any one of claims 4-10, wherein said first subunit comprises an amino acid sequence having at least 80% sequence identity to residues 198-344 of any one of SEQ ID NOs: 22-24 or residues 7-153 of any one of SEQ ID NOs: 25-28, and wherein said second subunit comprises an amino acid sequence having at least 80% sequence identity to residues 7-153 of any one of SEQ ID NOs: 22-24 or residues 198-344 of any one of SEQ ID NOs: 25-28.

### Claim 12 (depends on 4, 5, 6, 7, 8, 9, 10, 11)

The engineered meganuclease of any one of claims 4-11, wherein said first subunit comprises residues 198-344 of any one of SEQ ID NOs: 22-24 or residues 7-153 of any one of SEQ ID NOs: 25-28.

### Claim 13 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12)

The engineered meganuclease of any one of claims 4-12, wherein said second subunit comprises residues 7-153 of any one of SEQ ID NOs: 22-24 or residues 198-344 of any one of SEQ ID NOs: 25-28.

### Claim 14 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The engineered meganuclease of any one of claims 4-13, wherein said engineered meganuclease comprises a linker, wherein said linker covalently joins said first subunit and said second subunit.

### Claim 15 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The engineered meganuclease of any one of claims 4-14, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 22-28.

### Claim 16 (depends on 1, 2, 3)

The engineered meganuclease of any one of claims 1-3, wherein said recognition sequence comprises SEQ ID NO: 16.

### Claim 17 (depends on 16)

The engineered meganuclease of claim 16, wherein said HVR1 region comprises an amino acid sequence having at least 80% sequence identity to residues 215-270 of any one of SEQ ID NOs: 33-39.

### Claim 18 (depends on 16, 17)

The engineered meganuclease of claim 16 or claim 17, wherein said HVR1 region comprises residues corresponding to residues 215, 217, 219, 221, 223, 224, 229, 231, 233, 235, 237, 259, 261, 266, and 268 of any one of SEQ ID NOs: 33-39.

### Claim 19 (depends on 16, 17, 18)

The engineered meganuclease of any one of claims 16-18, wherein said HVR1 region comprises residues 215-270 of any one of SEQ ID NOs: 33-39.

### Claim 20 (depends on 16, 17, 18, 19)

The engineered meganuclease of any one of claims 16-19, wherein said HVR2 region comprises an amino acid sequence having at least 80% sequence identity to residues 24-79 of any one of SEQ ID NOs: 33-39.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The engineered meganuclease of any one of claims 16-20, wherein said HVR2 region comprises residues corresponding to residues 24, 26, 28, 30, 32, 33, 38, 40, 42, 44, 46, 68, 70, 75, and 77 of any one of SEQ ID NOs: 33-39.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The engineered meganuclease of any one of claims 16-21, wherein said HVR2 region region comprises residues 24-79 of any one of SEQ ID NOs: 33-39.

### Claim 23 (depends on 16, 17, 18, 19, 20, 21, 22)

The engineered meganuclease of any one of claims 16-22, wherein said first subunit comprises an amino acid sequence having at least 80% sequence identity to residues 198-344 of any one of SEQ ID NOs: 33-39, and wherein said second subunit comprises an amino acid sequence having at least 80% sequence identity to residues 7-153 of any one of SEQ ID NOs: 33-39.

### Claim 24 (depends on 16, 17, 18, 19, 20, 21, 22, 23)

The engineered meganuclease of any one of claims 16-23, wherein said first subunit comprises residues 198-344 of any one of SEQ ID NOs: 33-39.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The engineered meganuclease of any one of claims 16-24, wherein said second subunit comprises residues 7-153 of any one of SEQ ID NOs: 33-39.

### Claim 26 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The engineered meganuclease of any one of claims 16-25, wherein said engineered meganuclease comprises a linker, wherein said linker covalently joins said first subunit and said second subunit.

### Claim 27 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The engineered meganuclease of any one of claims 16-26, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 33-39.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A polynucleotide comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27.

### Claim 29 (depends on 28)

The polynucleotide of claim 28, wherein said polynucleotide is an mRNA.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29)

The polynucleotide of claim 29, wherein said mRNA is a polycistronic mRNA encoding one or more of said engineered meganucleases of claims 1-27.

### Claim 31 (depends on 30)

The polynucleotide of claim 30, wherein said polycistronic mRNA encodes:
(a) an engineered meganuclease which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 12; and
(b) an engineered meganuclease which recognizes and cleaves a recognition sequence comprising SEQ ID NO: 16.

### Claim 32 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 30, 31)

The polynucleotide of claim 30 or claim 31, wherein said polycistronic mRNA encodes:
(a) said engineered meganuclease of any one of claims 4-15; and
(b) said engineered meganuclease of any one of claims 16-27.

### Claim 33 (depends on 30, 31, 32)

The polynucleotide of any one of claims 30-32, wherein said polycistronic mRNA encodes an engineered meganuclease comprising an amino acid sequence of SEQ ID NO: 22 and encodes an engineered meganuclease comprising an amino acid sequence of SEQ ID NO: 33.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A recombinant DNA construct comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 34)

The recombinant DNA construct of claim 34, wherein said recombinant DNA construct comprises a cassette comprising a promoter and a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 34)

The recombinant DNA construct of claim 34, wherein said recombinant DNA construct comprises two or more cassettes, wherein each of said cassettes comprises a promoter and a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27, and wherein each of said engineered meganucleases has specificity for a different HBV recognition sequence.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 34)

The recombinant DNA construct of claim 34, wherein said recombinant DNA construct comprises a cassette comprising a promoter and a polycistronic nucleic acid sequence encoding one or more of said engineered meganucleases of any one of claims 1-27, wherein said promoter drives expression of said polycistronic nucleic acid sequence to generate a polycistronic mRNA in a target cell.

### Claim 38 (depends on 30, 31, 32, 33, 36)

The recombinant DNA construct of claim 36, wherein said polycistronic mRNA is said polycistronic mRNA of any one of claims 30-33.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 34)

The recombinant DNA construct of claim 34, wherein said recombinant DNA construct encodes a viral vector comprising said nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27.

### Claim 40 (depends on 39)

The recombinant DNA construct of claim 39, wherein said viral vector is a recombinant AAV vector.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A viral vector comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27.

### Claim 42 (depends on 41)

The viral vector of claim 41, wherein said viral vector is a recombinant AAV vector.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 41)

The viral vector of claim 41, wherein said viral vector comprises a cassette comprising a promoter and a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 41)

The viral vector of claim 41, wherein said viral vector comprises two or more cassettes, wherein each of said cassettes comprises a promoter and a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-27, and wherein each of said engineered meganucleases has specificity for a different HBV recognition sequence.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 41)

The viral vector of claim 41, wherein said viral vector comprises a cassette comprising a promoter and a polycistronic nucleic acid sequence encoding one or more of said engineered meganucleases of any one of claims 1-27, wherein said promoter drives expression of said polycistronic nucleic acid sequence to generate a polycistronic mRNA in a target cell.

### Claim 46 (depends on 30, 31, 32, 33, 45)

The viral vector of claim 45, wherein said polycistronic mRNA is said polycistronic mRNA of any one of claims 30-33.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A pharmaceutical composition for treatment of a subject having hepatitis B virus (HBV) or hepatocellular carcinoma caused by HBV, said pharmaceutical composition comprising a pharmaceutically acceptable carrier and:
(a) a nucleic acid encoding said engineered meganuclease of any one of claims 1-27; or
(b) said engineered meganuclease of any one of claims 1-27.

### Claim 48 (depends on 29, 30, 31, 32, 33, 47)

The pharmaceutical composition of claim 47, wherein said nucleic acid encoding said engineered meganuclease is said mRNA of any one of claims 29-33.

### Claim 49 (depends on 34, 35, 36, 37, 38, 39, 40, 47)

The pharmaceutical composition of claim 47, wherein said pharmaceutical composition comprises said recombinant DNA construct of any one of claims 34-40.

### Claim 50 (depends on 41, 42, 43, 44, 45, 46, 47)

The pharmaceutical composition of claim 47, wherein said pharmaceutical composition comprises said viral vector of any one of claims 41-46.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 47)

The pharmaceutical composition of claim 47, wherein said pharmaceutical composition comprises said engineered meganuclease of any one of claims 1-27.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 47)

The pharmaceutical composition of claim 47, wherein said pharmaceutical composition comprises two or more of said engineered meganucleases of any one of claims 1-27, wherein said engineered meganucleases have specificity for different HBV recognition sequences.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 47)

The pharmaceutical composition of claim 47, wherein said pharmaceutical composition comprises two or more nucleic acids encoding two or more of said engineered meganucleases of any one of claims 1-27, wherein said engineered meganucleases have specificity for different HBV recognition sequences.

### Claim 54 (depends on 29, 30, 31, 32, 33, 47)

The pharmaceutical composition of claim 47, wherein said pharmaceutical composition comprises one or more of said mRNAs of any one of claims 29-33 encapsulated within lipid nanoparticles.

### Claim 55

A method for treating a subject having HBV, said method comprising delivering to a target cell in said subject:
(a) a nucleic acid encoding an engineered meganuclease, wherein said engineered meganuclease is expressed in said target cell in vivo; or
(b) an engineered meganuclease;
wherein said engineered meganuclease has specificity for a recognition sequence in an ORF of the genome of at least two genotypes of the Hepatitis B virus, and wherein said engineered meganuclease recognizes and cleaves said recognition sequence in said target cell, and wherein the infection and/or proliferation of HBV in said subject is reduced or eliminated.

### Claim 56 (depends on 55)

The method of claim 55, wherein said recognition sequence is within an ORF of genotype A and one or more of genotype B (SEQ ID NO: 4), genotype C (SEQ ID NO: 5), genotype D (SEQ ID NO: 6), genotype E (SEQ ID NO: 7), genotype F (SEQ ID NO: 8), and genotype G (SEQ ID NO: 9).

### Claim 57 (depends on 55, 56)

The method of claim 55 or claim 56, wherein said recognition sequence is found within an ORF of at least 3, at least 4, at least 5, or at least 6 genotypes of the Hepatitis B virus.

### Claim 58 (depends on 55, 56, 57)

The method of any one of claims 55-57, wherein said recognition sequence is within at least one ORF encoding a protein selected from the group consisting of the polymerase (P) protein, the large surface (preS1/preS2/S) protein, the middle surface (preS2/S) protein, and the small surface (S) protein.

### Claim 59 (depends on 55, 56, 57, 58)

The method of any one of claims 55-58, wherein said recognition sequence comprises SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 10, or SEQ ID NO: 14.

### Claim 60 (depends on 55, 56, 57, 58, 59)

The method of any one of claims 55-59, wherein said recognition sequence comprises SEQ ID NO: 12.

### Claim 61 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 55, 56, 57, 58, 59)

The method of any one of claims 55-59, wherein said engineered meganuclease is said engineered meganuclease of any one of claims 4-15.

### Claim 62 (depends on 55, 56, 57, 58, 59)

The method of any one of claims 55-59, wherein said recognition sequence comprises SEQ ID NO: 16.

### Claim 63 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 62)

The method of claim 62, wherein said engineered meganuclease is said engineered meganuclease of any one of claims 16-27.

### Claim 64 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 55-63, wherein said method comprises administering to said subject said pharmaceutical composition of any one of claims 47-54.

### Claim 65 (depends on 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 55-64, wherein said engineered meganuclease, or said nucleic acid encoding said engineered meganuclease, is delivered to a target hepatocyte cell.
